Clinical trial · Observational

Identification of Novel Inflammation-related Biomarkers for Early Detection of Anthracycline-induced Cardiotoxicity in Breast Cancer Patients

NCT05298072CI-TRIAL-00057353unknownClinicalTrials.gov clinicaltrialsPublishedExplore in graph →

Summary

Brief summary (as posted)

This study aims to identify possible set of inflammatory biomarkers before, during and after anthracycline-based chemotherapy in breast cancer patients to identify (sub)clinical chemotherapy-related cardiac dysfunctionCRCD to identify patients who would benefit from additional cardioprotective therapy.

Conditions

Conditions (3)

Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.

Condition (as posted)	Mapped entity	Match	Confidence
Breast Cancer	Malignant Breast Neoplasm	CURATED_EXACT	0.92
Cardiotoxicity	—	UNRESOLVED	—
Heart Failure	—	UNRESOLVED	—

Interventions

Interventions (0)

Data not yet available

No intervention recorded.

Design

Arms and outcomes

Arms (0)

[]

Primary outcomes (1)

measure
Cardiotoxicity during observational period
timeFrame
continuous evaluation during observational period of 12 months
description
Defined according to IC-OS 2021 Consensus Criteria

Eligibility

Eligibility (as posted)

Sex: All
Minimum age: 18 Years

Show eligibility criteria text

Inclusion Criteria:

* initial diagnosis of breast cancer
* planned Anthracycline-based therapy
* first-line chemotherapy
* first visit before initiation of chemotherapy

Exclusion Criteria:

* previous chemotherapy
* medical history of cardiac disease
* inflammation-modulating medication
* medication with RAS inhibitors
* pregnancy
* autoimmune disease
* drug addictions
* unwilling or unable to provide informed consent

References

Publications (0)

Data not yet available

No reference posted for this study.